Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer

Histological status of axillary lymph nodes is an important prognostic factor in patients receiving surgery for breast cancer (BC). Sentinel lymph node (SLN) biopsy (B) has rapidly replaced axillary lymph node dissection (ALND), and is now the standard of care for axillary staging in patients with c...

Full description

Bibliographic Details
Main Authors:	Andreis, D, Bonardi, S, Allevi, G, Aguggini, S, Gussago, F, Milani, M, Strina, C, Spada, D, Ferrero, G, Ungari, M, Rocca, A, Nanni, O, Roviello, G, Berruti, A, Harris, A, Fox, S, Roviello, F, Polom, K, Bottini, A, Generali, D
Format:	Journal article
Language:	English
Published:	Elsevier 2016

Similar Items

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
by: Allevi, G, et al.
Published: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
by: Allevi, G, et al.
Published: (2013)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
by: Generali, D, et al.
Published: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
by: Fox, S, et al.
Published: (2011)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
by: Mele, T, et al.
Published: (2010)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
by: Fox, S, et al.
Published: (2011)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
by: Mele, T, et al.
Published: (2010)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
by: Generali, D, et al.
Published: (2009)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
by: Generali, D, et al.
Published: (2009)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
by: Generali, D, et al.
Published: (2008)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
by: Generali, D, et al.
Published: (2008)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
by: Generali, D, et al.
Published: (2006)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
by: Generali, D, et al.
Published: (2006)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
by: Generali, D, et al.
Published: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
by: Generali, D, et al.
Published: (2007)

P157 MammaPrint 8-year follow up results in patients with early breast cancer from a single-center Italian cohort study
by: E. Fiorino, et al.
Published: (2023-03-01)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
by: Generali, D, et al.
Published: (2006)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
by: Fox, S, et al.
Published: (2006)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
by: Maria Grazia Rodriquenz, et al.
Published: (2020-05-01)

Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use
by: Tomasz Cwalinski, et al.
Published: (2020-11-01)

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
by: Ottavia Bernocchi, et al.
Published: (2021-02-01)

Gut Microbiota Modulation in the Context of Immune-Related Aspects of <i>Lactobacillus</i> spp. and <i>Bifidobacterium</i> spp. in Gastrointestinal Cancers
by: Karolina Kaźmierczak-Siedlecka, et al.
Published: (2021-07-01)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
by: Foroni, C, et al.
Published: (2009)

Complete Mesogastric Excisions Involving Anatomically Based Concepts and Embryological-Based Surgeries: Current Knowledge and Future Challenges
by: Sergii Girnyi, et al.
Published: (2021-11-01)

Sodium butyrate in both prevention and supportive treatment of colorectal cancer
by: Karolina Kaźmierczak-Siedlecka, et al.
Published: (2022-10-01)

Molecular Basis of the Therapeutical Potential of Clove (<i>Syzygium aromaticum</i> L.) and Clues to Its Anti-COVID-19 Utility
by: Caterina Vicidomini, et al.
Published: (2021-03-01)

In Silico Investigation on the Interaction of Chiral Phytochemicals from <i>Opuntia ficus-indica</i> with SARS-CoV-2 M<sup>pro</sup>
by: Caterina Vicidomini, et al.
Published: (2021-06-01)

Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
by: Francesco Schettini, et al.
Published: (2023-07-01)

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
by: Milani, M, et al.
Published: (2009)

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis
by: Navid Sobhani, et al.
Published: (2021-10-01)

Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues
by: Luigi Marano, et al.
Published: (2023-01-01)

Summary of the Current Status of DNA Vaccination for Alzheimer Disease
by: Caterina Vicidomini, et al.
Published: (2023-11-01)

Dipentyl 2,6-diaminobenzo[1,2-b:4,5-b′]difuran-3,7-dicarboxylate
by: Giuseppina Roviello, et al.
Published: (2013-10-01)

Trends and perspectives in polymer science and technology : selected contributions from the conference in Naples (Italy), September 11-15, 2005 /
by: Pirozzi, B. (Beniamino), et al.
Published: (2006)

Editorial: Microbiota and metabolites in cancer immunotherapy
by: Giandomenico Roviello, et al.
Published: (2022-12-01)

DNA repair deficiency as circulating biomarker in prostate cancer
by: Martina Catalano, et al.
Published: (2023-01-01)

Crystal structure of N-n-dodecyl-bis(anthrylmethyl)amine, C42H47N
by: Beja A. Matos, et al.
Published: (2001-04-01)

N,N`-Bis(trimethylsilyl)carbodiimide – structure characteristics and reactivites
by: M. G. Shamina, et al.
Published: (2010-04-01)

1-Amino-N,N-dibenzyl-1-deoxy-alpha-D-tagato-pyranose methanol solvate
by: Harding, C, et al.
Published: (2005)

Natural and artificial binders of polyriboadenylic acid and their effect on RNA structure
by: Giovanni N. Roviello, et al.
Published: (2015-06-01)